Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 27kWORD 25k
10 September 2019
E-002267/2019(ASW)
Answer given by Mr Moedas on behalf of the European Commission
Question reference: E-002267/2019

The Innovative Medicines Initiative (IMI) has invested EUR 46 million in the pain area referred to by the Honourable Member.

EuropaIN(1), one of the funded projects, has carried out translational research that aims at understanding pain mechanisms, and at helping to develop novel analgesics and better biomarkers for pain. EuropaIN researchers demonstrated that antidepressants, such as amitriptyline, may relieve fibromyalgia syndrome (FMS) symptoms. However, a remarkable number of patients presents intolerable adverse effects or experience only a small relief of symptoms(2).

Horizon Europe will be the next Framework Programme investing in Research and Innovation for the period 2021 ‐2027. The implementation of Horizon Europe's programme-level objectives will be ensured by a multiannual Strategic Planning. This process will set out key strategic orientations for the implementation of Horizon Europe in a transparent and inclusive manner for the period 2021‐2024. Based on the Strategic Planning, a Work Programme will be developed during 2020 that will cover the needs for Research & Innovation for the period 2021‐2022. The Orientation Paper towards the Strategic Planning(3) indicated a possible partnership candidate Innovative Health Initiative (IHI) building upon IMI2.

The Strategic Planning will promote strong engagement with citizens and civil society and include extensive consultations with various stakeholders about research priorities. In the same context, a public consultation is ongoing(4), which together with the opportunity of participation in the Research &Innovation Days(5) in September 2019 and contributing to the upcoming public consultation on potential future partnerships, represent excellent opportunities also for FMS patients to share their perspectives and expectations.

(1)https://www.imi.europa.eu/projects-results/project-factsheets/europain
(2)CNS Drugs. 2012 Apr 1; 26(4):297-307. doi: 10.2165/11598970-000000000-00000. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis.
(3)https://ec.europa.eu/research/pdf/horizon-europe/ec_rtd_orientations-towards-the-strategic-planning.pdf
(4)https://ec.europa.eu/eusurvey/runner/HorizonEurope_Codesign_2021-2024
(5)https://ec.europa.eu/info/research-and-innovation/events/upcoming-events/european-research-and-innovation-days_en

Last updated: 11 September 2019Legal notice